Robust Prediction of Immune Checkpoint Inhibition Therapy for Non-Small Cell Lung Cancer
BackgroundThe development of immune checkpoint inhibitors (ICIs) is a revolutionary milestone in the field of immune-oncology. However, the low response rate is the major problem of ICI treatment. The recent studies showed that response rate to single-agent programmed cell death protein 1 (PD-1)/pro...
Main Authors: | Jiehan Jiang, Zheng Jin, Yiqun Zhang, Ling Peng, Yue Zhang, Zhiruo Zhu, Yaohui Wang, De Tong, Yining Yang, Jianfei Wang, Yadong Yang, Kui Xiao |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2021-04-01
|
Series: | Frontiers in Immunology |
Subjects: | |
Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.646874/full |
Similar Items
-
The Role of Molecular Profiling to Predict the Response to Immune Checkpoint Inhibitors in Lung Cancer
by: Courèche Kaderbhaï, et al.
Published: (2019-02-01) -
Prognostic Significance of SUVmax Combined With Lactate Dehydrogenase in Advanced Lung Cancer Patients Treated With Immune Checkpoint Inhibitor Plus Chemotherapy: A Retrospective Study
by: Linping Ke, et al.
Published: (2021-05-01) -
Blood-based Biomarkers in the Immune Checkpoint Inhibitor Treatment in
Non-small Cell Lung Cancer
by: Peng WANG, et al.
Published: (2021-07-01) -
Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer
by: Loïck Galland, et al.
Published: (2021-06-01) -
Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
by: Boris Duchemann, et al.
Published: (2020-12-01)